HIV :: New treatment model for HIV
Treatment of HIV patients must balance the need to suppress viral replication against the harmful side effects and significant cost to the patient of antiretroviral therapy.
Viral
HIV :: Major breakthrough in understanding how HIV interferes with infected cell division
Dr. ?ric A. Cohen, a researcher at the IRCM (Institut de recherches cliniques de Montr?al), and his team will publish on Friday, July 13, in PLoS Pathogens a discovery that could lead to the development of a new class of drugs to combat HIV.
Liver Cancer :: Antibody retards growth and induces death in liver cancer cells
Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.
Kaposi Sarcoma :: Kaposi sarcoma arises independently from multiple cells
Kaposi sarcoma is unique among cancers because most tumors grow from a small number of different cells, whereas nearly all other cancers arise from a single cell, according to a study published online July 10 in the Journal of the National Cancer Institute.
Pancreatic Cancer :: Gene therapy eradicates pancreatic cancer in preclinical trial
A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.
HIV :: PREZISTA Phase III Study meets primary objective in HIV patients
Results from a Phase 3 head-to-head study showed that a significantly greater percent (77 percent) of treatment-experienced HIV-1 infected adults* taking Prezista? (darunavir)/ritonavir, with an optimised background regimen (OBR) of antiretroviral agents, reached a viral load of less than 400 copies/mL at week 48, compared to 68 percent of patients taking the widely prescribed medication lopinavir/ritonavir, with OBR, in a per-protocol analysis (95 percent confidence interval 2-16). In addition, significantly more patients receiving darunavir/r in this study reached an undetectable viral load (<50 copies/mL) compared to patients taking lopinavir/r (71 percent vs. 60 percent).
Lung Cancer :: Gene variations directly link inflammation to an increased risk for lung cancer
Variations in two genes related to inflammation may be a major risk factor for developing lung cancer, according to a team of scientists from the National Cancer Institute and the University of Texas M. D. Anderson Cancer Center.
Multiple Sclerosis :: Antibody linked to MS significantly higher in spinal fluid of blacks
An antibody frequently used as a diagnostic marker for multiple sclerosis (MS) is present at greater levels in the cerebrospinal fluid of blacks with MS than Caucasians with the disease.
Brain Cancer :: M. D. Anderson team identifies new oncogene for brain cancer
An overexpressed gene found at the scene of a variety of tumors is implicated in the development of two types of malignant brain cancer in a paper by researchers at The University of Texas M. D. Anderson Cancer Center to be published in the Proceedings of the National Academy of Sciences.
SARS :: Human antibodies that block human and animal SARS viruses identified
An international team of investigators has identified the first human antibodies that can neutralize different strains of virus responsible for outbreaks of severe acute respiratory syndrome (SARS). The researchers used a mouse model and in vitro assays (lab tests) to test the neutralizing activity of the antibodies.